Virax Biolabs GroupVRAX -0.64%37 Current Ratio is 11.37 as of Sep. 2025, which is 56% above its 10-year median of 7.27. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Virax Biolabs Group ranks better than 80.91% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Virax Biolabs Group's current ratio for the quarter that ended in Sep. 2025 was 11.37.
Virax Biolabs Group has a current ratio of 11.37. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Virax Biolabs Group's Current Ratio or its related term are showing as below:
VRAX'
s Current Ratio Range Over the Past 10 Years
Min: 0.02 Med: 7.27 Max: 25.92
Current: 11.37
During the past 6 years, Virax Biolabs Group's highest Current Ratio was 25.92. The lowest was 0.02. And the median was 7.27.
VRAX's Current Ratio is ranked better than 80.91% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs VRAX: 11.37
Virax Biolabs Group (NAS:VRAX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Virax Biolabs Group Current Ratio Related Terms
Virax Biolabs Group Current Ratio Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs BBLG, PKTX, OGEN: Current Ratio Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Current Ratio of 11.37 as of Sep. 2025. This is 56% above median its historical median of 7.27. Over the past decade, Virax Biolabs Group's Current Ratio has ranged from 0.02 to 25.92. According to the industry distribution chart, Virax Biolabs Group ranks #269 out of 1409 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Virax Biolabs Group's Current Ratio too high?
Virax Biolabs Group's current Current Ratio of 11.37 is 56% above median its 10-year median of 7.27. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 25.92. The Biotechnology industry median Current Ratio is 3.89. Virax Biolabs Group's value of 11.37 is 192.3% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #269 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Current Ratio compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #269 out of 1409 companies for Current Ratio. This places Virax Biolabs Group in the top 19% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Virax Biolabs Group's value of 11.37 is 192.3% above this benchmark. Historically, Virax Biolabs Group's own Current Ratio has ranged from 0.02 to 25.92 over the past decade. While the company's 10-year median is 7.27 vs. the industry median of 3.89, Virax Biolabs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Current Ratio of 11.37 is 192.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Current Ratio is 11.37, which is 56% above median its own 10-year median of 7.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Current Ratio is 11.37, which is 56% above median its 10-year median of 7.27 and 192.3% above the Biotechnology industry median of 3.89. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Current Ratio is 11.37 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
Current Ratio: 11.37 (56% above median its 10-year median of 7.27)
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
Industry Position: 192.3% above the Biotechnology median (#269 of 1409)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
